Ixico PLC | Balance Sheet

Fiscal year is October-September. All values GBP Thousands.
2012
2014
2015
2016
2017
2018
Cash & Short Term Investments
8,887.20
3,294.00
1,934.00
3,120.00
2,414.00
7,861
Total Accounts Receivable
1,421.30
1,262.00
1,713.00
1,727.00
1,722.00
2,110
Other Current Assets
218.30
217.00
176.00
188.00
185.00
259
Total Current Assets
10,526.90
4,773.00
3,823.00
5,035.00
4,321.00
10,230
Net Property, Plant & Equipment
62.30
120.00
116.00
88.00
60.00
77
Intangible Assets
-
520.00
300.00
559.00
128.00
32
Total Assets
10,589.20
5,413.00
4,239.00
5,682.00
4,509.00
10,339
Accounts Payable
524.00
398.00
370.00
216.00
270.00
Other Current Liabilities
1,691.50
1,099.00
1,100.00
1,269.00
1,305.00
Total Current Liabilities
2,215.50
1,497.00
1,470.00
1,485.00
1,575.00
Deferred Taxes
-
104.00
60.00
112.00
19.00
Total Liabilities
2,215.50
1,601.00
1,530.00
1,597.00
1,594.00
Common Equity (Total)
8,373.70
3,812.00
2,709.00
4,085.00
2,915.00
Total Shareholders' Equity
8,373.70
3,812.00
2,709.00
4,085.00
2,915.00
Total Equity
8,373.70
3,812.00
2,709.00
4,085.00
2,915.00
Liabilities & Shareholders' Equity
10,589.20
5,413.00
4,239.00
5,682.00
4,509.00

About Ixico

View Profile
Address
Griffin Court
London Greater London EC1A 9PN
United Kingdom
Employees -
Website http://ixico.com/
Updated 07/08/2019
IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was founded by Derek Lionel Glendon Hill on November 28, 1995 and is headquartered in London, the United Kingdom.